Salt Composition in both
Salt Composition
Rosuvastatin 20mg(same for both)
You Searched
Strip of 15 tablets
We only sell the best substitute from top brands
Our Recommendation
Rosu HDL 20mg Tablet 10s
Strip of 10 tablets
2,791+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Submit your medicinesView more medicineshttpsSU_PRoot_DSR.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.ngram.nolv.ofram.nolv.ofram.nolv.ofram.ngram.ngram.nolv.ofram.ngram.ngram.nolv.ofram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.nolv.ofram.ngram.ngram.nolv.ofram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.ngram.
Crestor, a widely prescribed statin medication, is a widely recognized and effective medication for the management of various cholesterol-related conditions. It works by reducing the amount of cholesterol that reaches the liver and helps to lower the risk of cardiovascular complications in patients at high risk of cardiovascular disease.
Crestor is manufactured by AstraZeneca, a leading global pharmaceutical manufacturer. It belongs to the statin family of drugs and works by reducing the amount of cholesterol that reaches the liver and helps to lower the risk of cardiovascular complications in patients at high risk of cardiovascular disease.
The global Crestor (Rosuvastatin) market has been experiencing significant growth. As of 2023, the market size was valued at USD 1.64 billion and is projected to reach USD 2.87 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period of 2024-2032[1][2][3].
Another report indicates that the market is expected to grow at a CAGR of 6.4% from 2024 to 2032. This growth is driven by the increasing prevalence of statin-related conditions, including cardiovascular diseases such as high blood pressure, and the growing awareness of the health consequences associated with these conditions[1].
The Crestor (Rosuvastatin) market is segmented based on several key factors, including product form, market penetration, market growth, and dynamics. The segmented by strength is highly encouraged by the increasing prevalence of statin-related conditions, particularly in regions with robust healthcare infrastructure and advanced research and development (HRN"[4].
The report provides valuable information on the market and helps stakeholders to business planning and monetize their initiatives. It helps stakeholders to capitalize on strategic developments and financial diversions to capitalize on the market demand for new products and formulations[1][4].
The Crestor (Rosuvastatin) market is competitive, with several major players like AstraZeneca, Apotex, Novartis/Sigma-BOTOS, and Bayer/Glenmark participating in the market. The report provides valuable insights on each player, including market players’ regional distribution channels, competitive positioning, market presence, and government regulatory approvals[1][4].
The COVID-19 pandemic has significantly impacted the Crestor (Rosuvastatin) market. As stated in the release, "The pandemic has led to an increased risk of cardiovascular events, strokes, and other serious health complications. As a result, the number of people suffering from these conditions has increased, driving the demand for statin medications like Crestor[1]."
The report also highlights the impact of the COVID-19 pandemic on the market, with various studies indicating a significant drop in the number of deaths in patients treated with statins due to cardiovascular events[5].
The Crestor (Rosuvastatin) market offers a competitive landscape, with several major players such as Apotex, Bayer/Glenmark, GlaxoSmithKline, and others. The report provides valuable information on the market, including companies’ regional distribution channels, government regulatory approvals, and direct-to-consumer advertising strategies[5].
The market is highly competitive, with several major players such as AstraZeneca, Apotex, Novartis/Sigma-BOTOS, and Bayer/Glenmark participating in the market. The report offers valuable information on each player, including their competitive positioning, market presence, and government regulatory approvals[5].
The Crestor (Rosuvastatin) market is segmented into North America, Europe, Asia Pacific (AP), Middle East and Africa (MEA), and Latin America and the Caribbean (LAC). The report provides valuable information on each region, including governments’ planning regulations, HR landscape, government approvals, direct-to-consumer advertising strategies, and direct-to-consumer promotion strategies[5].
AstraZeneca, one of the world’s largest pharmaceutical companies, recently announced it would be changing the name of its cholesterol drug Crestor, from Crestor to Lipitor (atorvastatin), as part of a broader strategy to reduce the cost of its drugs, said its spokesperson. The company is also launching new generic versions of the drug, but the change will be made through a partnership with a drug rep.
“This is another step in an effort to ensure the safety of Crestor and Lipitor and potentially improve patients’ access to the medicines they need,” said Michael O’Leary, AstraZeneca’s president and CEO. “This is an important step to ensuring that patients can get the care they need and that Crestor and its generic version will remain available for the full cost of the medication.”
The change was announced at an event at the annual meeting of the American College of Physicians in Washington, D. C. AstraZeneca said it planned to launch its generic Crestor at the end of the year. The company will not disclose the cost of the new generic until the year after the company’s decision, O’Leary said.
“I don’t believe it will be difficult for patients to pay more for Crestor than it is currently used to,” he said. “The company is committed to making sure that patients have access to the medicines they need.”
The company is currently working on another generic version of Crestor, which will be available in the U. S. in about 20 years, O’Leary said.
“We’ve been working on Crestor since it was first launched in 2003 and it is important that we continue to make sure patients have access to it,” he said. “We’re working on it for the full cost of the medicine and we hope that by working with the drug rep that we’ll continue to be able to make sure that the patients get the care they need.”
In October, the company will launch its generic version of Crestor at a cost of $11.66 per month. It will be available in a number of strengths, including 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, and 600 mg.
In December, the company will be launching its generic version of Lipitor, and will begin launching its new generic in 20 years. It will be available in several strengths including 50 mg, 75 mg, 100 mg, 200 mg, and 300 mg.
“I don’t know when we will be able to do the new generic version of Crestor,” O’Leary said. “I do know that it’s a great deal. We can’t give it up. We will have to make sure that it’s a safe and effective generic.”
In November, the company announced it was moving its sales force to New Jersey, where it plans to introduce the drug at its Nov. 13 meeting, O’Leary said.
“I’m excited about the new launch of Crestor at this year’s meeting,” O’Leary said. “We’re also looking at other plans for new generic versions of Crestor. We are doing well in the pipeline.”
For the Nov. 13 meeting, AstraZeneca will be meeting with the company’s president, John R. DeWine, at 11 a.m. Eastern, in New Jersey. DeWine will also serve as executive chairman.
“We are looking forward to meeting with AstraZeneca as soon as possible,” DeWine said. “We’ll be meeting with AstraZeneca to discuss the new Crestor and other medications.”
In addition, AstraZeneca said it would be launching its generic version of Crestor at its Oct. 12 meeting, which is in New York. The company will also be working on a new product, including a cholesterol fighter, for a year.
“We are doing well in the pipeline,” DeWine said. “We have been working on a new product and hope to be able to launch it at the end of the year.
VIDEO
Crestor (rosuvastatin) is an oral antacid medication that is used to treat high blood pressure, cholesterol, and liver problems.
Crestor (rosuvastatin) is usually taken orally once a day.
Crestor (rosuvastatin) works by relaxing the muscles in your arteries and veins and increasing blood flow to your heart muscle.
Taking Crestor (rosuvastatin) can cause serious side effects, including:
Crestor (rosuvastatin) is a statin that is used to lower cholesterol levels in patients with an elevated cholesterol level. It lowers your total cholesterol by blocking the enzyme called HMG-CoA reductase, which is responsible for turning in the body into its isoenzyme. statins lower total cholesterol to lower bad cholesterol levels.
Learn more about.
Crestor (rosuvastatin) and Ezallor (crestor) are two oral medications that lower high cholesterol levels and reduce the symptoms of atherosclerosis and other serious health problems.
Both Crestor (crestor) and Ezallor (rosuvastatin) are used to treat high cholesterol levels and reduce symptoms of atherosclerosis and other serious health problems.
Crestor (rosuvastatin) is not recommended if you have the following conditions and are taking:
Learn more about it at or contact your doctor, nurse, or pharmacist.
Follow your doctor's directions and dosage as prescribed by your doctor.
Crestor (rosuvastatin) should be taken exactly as prescribed by your doctor. Take it orally, with or without food, once a day.
Video that shows how to take Crestor (rosuvastatin):
Take the missed dose as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and take the next dose at the regular time.
Take the medicine as per your doctor's instructions.
Most people do not experience serious side effects. Learn more here and.
Generic name:RosuvastatinDrug class:
by Drugs.com. Last updated on Apr 27, 2025.
is used to treat high cholesterol and reduce the risk of heart disease in adults and children 12 years of age and older (the age of 40). It works by reducing the amount of cholesterol that your body makes and helps to prevent further buildup of cholesterol. You may also need to take rosuvastatin at least three months before or six months after having a meal or at least two weeks before having a meal. Your doctor may tell you to take rosuvastatin with food or milk to reduce stomach upset. You may be prescribed a low dose of rosuvastatin (40 mg) when you have a cholesterol level of less than 40 mg/dl (3.6 mmol/l) of cholesterol. Rosuvastatin should be taken with food. You may be prescribed a low dose of rosuvastatin (40 mg) when you have a cholesterol level of less than 40 mg/dl (3.
Stade de France Pharmacy